Meeting
2018 Gastrointestinal Cancers Symposium
The 12-gene Oncotype DX Colon Recurrence Score (RS) test: Experience with > 20,000 stage 2 patients (pts).
Authors
Helen Bailey
Genomic Health, Inc., Redwood City, CA
Helen Bailey , Michelle Turner , Melissa C Stoppler , Calvin Chao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 618)
DOI
10.1200/JCO.2018.36.4_suppl.618
Abstract #
618
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Treatments and clinical outcomes in stage II colon cancer (CC) patients (pts) with 12-gene Oncotype DX Colon Recurrence Score assay-guided therapy: Real-world data.
First Author: Baruch Brenner
Poster
2021 ASCO Annual Meeting
Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.
First Author: Greg Yothers
Poster
2018 ASCO Annual Meeting
A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).
First Author: Shigeki Yamaguchi
Poster
2017 ASCO Annual Meeting
Recurrence risk factors and outcome stratification in stage II colon cancer patients: A subanalysis of the SACURA trial.
First Author: Megumi Ishiguro